A shared piece on how the spread of GLP-1 drugs could shape how people who aren't taking them feel. Only the headline is available here.
Recap by typeshit. Post by Facebook on Facebook.
The EMA's CHMP amended its type 2 diabetes indication, and Italian diabetologists say Italy could be the first European country to offer the once-weekly combo.
26:19
A personal update from TakingWeightOff on life after stopping tirzepatide, three weeks in, and what caught them off guard.
Nyah Phengsitthy reports Lilly is staking out a new battlefront around an unapproved obesity treatment. The full story has the details.
A history of drug advertising, from opium-laced tonics and Radithor to the 1938 law after Elixir Sulfanilamide killed over 100 people. Semaglutide is mostly a hook.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
Loading…